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Abstract
Maintenance of the complex phenotype of primary hepatocytes in vitro represents a
limitation for developing liver support systems and reliable tools for biomedical
research and drug screening. We herein aimed at developing a biosystem able to
preserve human and rodent hepatocytes phenotype in vitro based on the main
characteristics of the liver sinusoid: unique cellular architecture, endothelial
biodynamic stimulation, and parenchymal zonation. Primary hepatocytes and liver
sinusoidal endothelial cells (LSEC) were isolated from control and cirrhotic human or
control rat livers and cultured in conventional in vitro platforms or within our liver‐
resembling device. Hepatocytes phenotype, function, and response to hepatotoxic
drugs were analyzed. Results evidenced that mimicking the in vivo sinusoidal
environment within our biosystem, primary human and rat hepatocytes cocultured
with functional LSEC maintained morphology and showed high albumin and urea
production, enhanced cytochrome P450 family 3 subfamily A member 4 (CYP3A4)
activity, and maintained expression of hepatocyte nuclear factor 4 alpha (hnf4α) and
transporters, showing delayed hepatocyte dedifferentiation. In addition, differen-
tiated hepatocytes cultured within this liver‐resembling device responded to acute
treatment with known hepatotoxic drugs significantly different from those seen in
conventional culture platforms. In conclusion, this study describes a new bioengi-
neered device that mimics the human sinusoid in vitro, representing a novel method
to study liver diseases and toxicology.
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1 | INTRODUCTION
Primary hepatocytes are highly specialized cells used as the main tool
for assessing hepatotoxicity, cellular transplantation, biomedical
research, and as an essential component of active bioartificial devices
to support liver function (Baccarani et al., 2004; Godoy et al., 2013;
Nicolas et al., 2017). Nevertheless, specific functions and differen-
tiated phenotype are progressively lost when hepatocytes are cultured
in vitro, leading to loss of enzymatic activity and detoxification
capacity, changes in cell morphology and function, and deregulation of
transporters expression (Elaut et al., 2006; Rowe et al., 2010). Several
approaches have been proposed to overcome/delay this dedifferentia-
tion process, including sandwich cultures, spheroid systems, or the
development of sinusoidal‐mimicking devices known as liver‐on‐a‐chip
(Fraczek, Bolleyn, Vanhaecke, Rogiers, & Vinken, 2013; Lauschke,
Hendriks, Bell, Andersson, & Ingelman‐Sundberg, 2016).
Liver‐on‐a‐chip are usually low‐volume miniaturized devices that
enable the culture of hepatic cells in different configurations both
under flow or static conditions. In a healthy liver, hepatocyte
functions are partially maintained by microenvironmental signaling
from neighboring cells; for this reason, hepatocytes within these
liver‐resembling devices are often studied in coculture with
nonparenchymal cells. Liver sinusoidal endothelial cells (LSEC),
hepatic macrophages, and hepatic stellate cells constitute the major
populations of nonparenchymal cells in the liver (Arias et al., 2009;
Wisse et al., 1996). They play central roles both in liver physiology
and pathology, and therefore cannot be ignored to generate reliable
coculture systems (Marrone, Shah, & Gracia‐Sancho, 2016; Usta
et al., 2015), and to guarantee a greater translational capability in
studies using human liver cells.
Considering the above‐mentioned background, the design,
development, and future applicability of a liver‐on‐a‐chip device
requires accurate selection of the hepatic cell type to be cultured, as
well as the internal and external environmental stimuli that will
modulate the phenotype of hosted cells (Fraczek et al., 2013).
Although several authors used immortalized human cell lines to
substitute fresh hepatocytes within their microfluidic devices (Bavli
et al., 2016; Ma et al., 2016; Rennert et al., 2015) these lack a
significant part of liver‐specific functions (Kanebratt & Andersson,
2008; Wilkening, Stahl, & Bader, 2003). Regarding the microenviron-
ment modulating hepatocytes phenotype, in nature parenchymal
cells are partly maintained through paracrine communication from
LSEC. Indeed, the key role of LSEC in the liver has been patent not
only for being the first cells sensing liver injury (Hide et al., 2016;
McCuskey, 2006) but also for maintaining and enhancing hepato-
cytes phenotype (Bhatia, Balis, Yarmush, & Toner, 1999; Kasuya,
Sudo, Mitaka, Ikeda, & Tanishita, 2011; Liu, Li, Yan, Wei, & Li, 2014;
Marrone et al., 2016). In the specific field of liver‐on‐a‐chip, LSEC
have been questionably replaced by general endothelial cells, such as
human aortic endothelial cells (HAEC) (Ma et al., 2016), human
umbilical vein endothelial cells (HUVEC) (H. Lee & Cho, 2016; J. W.
Lee et al., 2016; Rennert et al., 2015), stable human endothelial cell
line (EA.hy926) (Prodanov et al., 2016) or BAEC (Kang et al., 2015)
among others. However, primary LSEC are rarely found in this
context, especially when using human liver cells.
We hypothesized that maintaining a physiological sinusoid‐like
environment allowing the paracrine communication between hepa-
tocytes and functional LSEC would provide a suitable milieu for
maintaining the phenotype and function of these cells, delaying
hepatocyte dedifferentiation, and being more sensitive in predicting
hepatotoxicity than conventional two‐dimensional in vitro cultures.
To test this hypothesis, and mainly focusing on its translational
applicability, the primary aim of our study was to cautiously
characterize the phenotype and function of primary human hepato-
cytes cocultured with primary functional human LSEC within a fluidic
device that mimics the hepatic sinusoid (Illa et al., 2014) and compare
with conventional configurations. In addition, and as a secondary aim,
we studied this liver‐on‐a‐chip as a potential tool for preclinical
research on the fields of chronic liver disease and hepatotoxicity.
Supplementary experiments using primary rat cells were performed
to endorse the model in a non‐human experimental scenario.
2 | MATERIALS AND METHODS
2.1 | Isolation of human and rat hepatocytes
and LSEC
Human cells were isolated from remnant tissue approximately weighing
20 g obtained after human partial hepatectomy to excise tumor
metastasis from colon carcinoma (for healthy cells; note that obtained
peritumoral tissue was confirmed as “normal” by anatomical pathologists)
and from the discarded tissue after liver transplantation (chronic ethanol
etiology, for cirrhotic cells). Ethics Committee of the Hospital Clínic de
Barcelona approved the experimental protocol (HCB/2015/0624), and in
all cases, patients received and agreed to an informed consent.
Rodent cells were isolated from male Wistar Han rats (Charles River
Laboratories Barcelona, Spain) weighing 300–350 g kept at the
University of Barcelona Faculty of Medicine facilities with controlled
temperature (19.7 ± 2°C), humidity (52 ± 5%) and light/dark cycle (12 hr
each). Animals were fed ad libitum with water and standard rodent food
pellets. All experiments were approved by the Laboratory Animal Care
and Use Committee of the University of Barcelona and were conducted
in accordance with the European Community guidelines for the
protection of animals used for experimental and other scientific purposes
(European Economic Community Directive 86/609).
Hepatocytes and LSEC were isolated using standardized protocols
(Gracia‐Sancho et al., 2007; Oie, Snapkov, Elvevold, Sveinbjornsson, &
Smedsrod, 2016) and cultured as detailed in Supporting Information
Materials. Highly pure and viable cells were used. Cell density under each
individual experimental condition was 106 hepatocytes and 2.5·105 LSEC.
2.2 | Liver‐on‐a‐chip technology and culture of
primary cells
Our team has recently developed a fluidic device whose detailed
fabrication and features were previously described in Illa et al. (2014)
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and is herein termed Exoliver. Briefly, it consists of a sinusoidal‐
mimicking layered structure that allows coculture of different cell
types and fluidic stimulation of the top layer of the device. LSEC were
grown in the upper area on a hydrophilic polytetrafluoroethylene
microporous membrane with homogeneous and continuous shear
stress stimulation, whereas hepatocytes were plated in the lower
poly (methyl methacrylate) area of the device. Dynamic Exoliver
configurations started with a shear stress stimulus of 0.1 dyn/cm2
that was gradually increased during the first 2 hr of culture until
reaching 1.15 dyn/cm2 (1.5 ml/min), with a total amount of 43ml
unidirectional recirculating culture media. Exoliver, reservoir, filters,
and most of the tubing were placed inside an incubator to maintain
physiological conditions (37°C, 5% CO2). Five different experimental
configurations were considered for this study (Figure 1).
The day after the isolation, hepatocytes and LSEC were rinsed twice
with the Dulbecco phosphate‐buffered saline (02‐023‐1A; Reactiva), and
media was changed to Dulbecco modified Eagle medium (DMEMF12;
11320074; Gibco) supplemented with 2.97% dextran (31392; Sigma,
Darmstadt, Germany) to simulate blood viscosity, 2% fetal bovine serum
(04‐001‐1A; Reactiva), 1% penicillin plus 1% streptomycin (03‐331‐1C;
Reactiva), 1% endothelial cell growth supplement (BT‐203; Biomedical
Technologies), 1% heparin (H3393; Sigma), 1% L‐glutamine (25030‐024;
Gibco), 1% amphotericin B (03‐029‐1C; Reactiva), 1 nM dexamethasone
(D4902; Sigma), 10 ng/ml Epidermal Growth Factor (E4127; Sigma),
1.5 nM glucagon (16941-32-4, Novo Nordisk), 15 nM hydrocortisone
(H0888, Sigma), and 1 µM insulin (Humulin S, Lilly S.A.).
Then, transwells and bioreactors were assembled and perfusion
of the dynamic conditions started. Human and rat cultures were
maintained for 3 or 7 days, and then disassembling of the bioreactor
was performed to separately analyze both cell types. Cell super-
natant analysis, quantitative polymerase chain reaction, and CYP3A4
assay were performed under all experimental conditions mentioned
above, as described in Supporting Information Methods.
Once concluded that there were no significant differences in the
studied markers between conventional mono‐ and coculture config-
urations, we decided to eliminate the conventional coculture
condition in the 7‐day human experiments to maximize cell seeding
under the other conditions obtained from the scarce liver tissue
available after surgery.
2.3 | Statistics and data analyses
Statistical analysis was performed with SPSS Statistics19 software
for Windows. Results were expressed as mean ± standard error of
mean. To assess differences between groups, we performed one‐way
analysis of variance with least significant difference (LSD) post‐hoc
tests when variables were parametric and Mann–Whitney test for
nonparametric variables. Differences between groups were consid-
ered as significant when p value ≤ 0.05. Each experiment was
performed in duplicate from at least n = 3 independent isolations.
3 | RESULTS
3.1 | Exoliver maintains human hepatocyte
phenotype and function
Maintenance of human healthy hepatocytes phenotype was assessed
under five experimental conditions (Figure 1, top): hepatocytes
cultured in two conventional configurations (monoculture and
coculture with LSEC) and within Exoliver in three different
configurations: coculture with LSEC stimulated with continuous and
homogenous shear stress (optimal condition), coculture without
F IGURE 1 Experimental conditions analyzed. Top, in vitro conventional culture methods: (a) monoculture in 35mm petri dish and
(b) coculture in transwell. Exoliver conditions: (c) dynamic coculture (optimal condition), (d) static coculture, and (e) dynamic monoculture.
Hepatocytes represented in red and liver sinusoidal endothelial cells (LSEC) in yellow. Bottom, Exoliver design and circuit components [Color
figure can be viewed at wileyonlinelibrary.com]
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shear stress (which leads to LSEC dysfunction Supporting Informa-
tion Figure 1) and hepatocytes monoculture with indirect flow
stimulus (without paracrine interactions from LSEC).
Synthetic capacity of hepatocytes was evaluated as active
albumin and urea production and release to the culture media.
Human primary hepatocytes cultured under the Exoliver dynamic
coculture condition showed higher albumin synthesis when com-
pared with all static conditions after 3 days (Figure 2a) and to a lesser
extent after 7 days (Figure 2d) of culture. Hepatocytes cultured using
Exoliver dynamic monoculture configuration produced higher albu-
min than static configurations after 3 days, but this was no longer
seen after 7 days of culture. At 3 days of culture, urea production
was highly increased in dynamic coculture configurations and
partially maintained by dynamic monoculture condition (Figure 2a).
At 7 days of culture (Figure 2d), both dynamic conditions showed
increased urea production compared with all static configurations.
Primary human hepatocytes in coculture with shear stress‐
stimulated LSEC inside Exoliver showed superior cytochrome P450
family 3 subfamily A member 4 (CYP3A4) activity compared with all
culture conditions both after 3 and 7 days of culture (Figure 2b,e,
respectively). Although CYP3A4 activity in the dynamic monoculture
configuration was partially increased after 3 days of culture, this
maintenance was no longer significantly different after 7 days of
culture, reinforcing the concept of maintenance of hepatocyte
function through paracrine interactions from functional LSEC in the
dynamic coculture condition.
Hepatocytes phenotype was further assessed by means of
expression of the master regulator hepatocyte nuclear factor 4
alpha (hnf4α), and the transporters ATP‐binding cassette subfamily C
member 3 (abcc3) and solute carrier family 22 member 1 (slc22a1).
hnf4α messenger RNA (mRNA) expression was increased under
Exoliver dynamic coculture condition after 3 days (Figure 2c)
although prevention of its downregulation was not reached after
7 days of culture (Figure 2f). Results derived from slc22a1 analyses
showed no significant differences in any analyzed group at 3 days of
study but exhibited higher expression of this marker under Exoliver
dynamic coculture condition compared with suboptimal Exoliver
configurations after 7 days of culture. Abcc3 mRNA upregulation was
prevented under all dynamic Exoliver conditions after 3 and 7 days of
culture compared with conventional culture configurations.
Conventional configurations showed no significant differences in
any of the studied parameters neither after 3 days nor 7 days of
culture.
Maintenance of hepatocytes phenotype using this liver‐on‐a‐chip
device was confirmed in a second species. Supporting Information
Figure 2 shows all data regarding coculture of rat primary
hepatocytes and LSEC.
3.2 | Exoliver prevents hepatocytes morphology
deterioration
Primary human or rat hepatocytes cultured in the previously described
conditions exhibited different morphology. The characteristic
polygonal shape and angular edges from freshly isolated hepatocytes
were gradually lost upon culture in conventional platforms. As shown
in Figure 3, hepatocytes became flattened with diffuse separation
between cells (Day 3), further acquiring myofibroblast‐like morphol-
ogy, finally leading to cell aggregation in clusters (Day 7). Prevention of
the in vitro dedifferentiation process in the optimal Exoliver
configuration was associated with maintenance of hepatocyte poly-
gonal shape both after 3 and 7 days of culture. Suboptimal Exoliver
configurations did not maintain hepatocyte morphology (Supporting
Information Figure 3). Considering all the collected data, translational
experiments of the device were performed using the optimal
configuration of the device and compared with conventional cell
culture method.
3.3 | Exoliver as a tool to study chronic liver
disease
Primary hepatocytes isolated from human cirrhotic livers and
cultured in the optimal Exoliver configuration (dynamic coculture
with functional LSEC) exhibited significantly better‐preserved
phenotype in comparison with cells in monoculture using
two‐dimensional conventional methods (Figure 4). Indeed, albumin
and urea production and secretion to the culture media was
significantly higher in Exoliver‐cultured hepatocytes. Moreover,
lower mRNA expression of the transporter abcc3 and higher
mRNA expression of the transporter slc22a1 were found in
hepatocytes cultured using the device, suggesting an overall
maintenance of hepatocyte phenotype.
3.4 | Exoliver as a tool to study hepatotoxicity
Human hepatocytes toxicity response was assessed using acute
overdose of the anti‐diabetic drug troglitazone, the catechol‐O‐
inhibitor for Parkinson’s disease tolcapone, the nonsteroideal anti‐
inflammatory drug diclofenac, and the widely prescribed anti‐pyretic
and analgesic drug acetaminophen.
Hepatotoxic effect of troglitazone (Figure 5a) was demonstrated
in hepatocytes cultured in the conventional two‐dimensional config-
uration; however, it showed no toxic effect on hepatocytes cultured
using Exoliver, as demonstrated by the vehicle‐comparable produc-
tion of the five parameters analyzed. Tolcapone‐derived hepatotoxi-
city in two‐dimensional cultured hepatocytes was shown as high
transaminases release to the culture media (Figure 5b) although no
significant effect was detected in albumin and urea production in
response to acute treatment with this drug. Hepatotoxicity derived
from tolcapone treatment was not seen in Exoliver‐cultured
hepatocytes, showing vehicle‐production urea and transaminases
and a significant increase in albumin synthesis.
High doses of diclofenac showed toxic effects on hepatocytes
(Figure 5c) in conventional cultures as well as in Exoliver‐cultured
hepatocytes. Although no significant changes were observed in active
urea and albumin synthesis, transaminases were significantly
increased in response to acute treatment with this drug.
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F IGURE 2 Evaluation of healthy primary human hepatocytes after 3 days (a–c) or 7 days (d–f) of culture under the experimental conditions
described in Figure 1. Synthetic capacity of hepatocytes was measured as albumin and urea secretion, phase I enzymes detoxification capacity
as cytochrome P450 family 3 subfamily A member 4 (CYP3A4) activity and cell phenotype markers as gene expression of the transcription
factor hepatocyte nuclear factor 4 alpha (hnf4α), solute carrier family 22 member 1 (slc22a1), and ATP‐binding cassette subfamily C member 3
(abcc3) transporters. Data derive from n = 4 independent experiments were normalized to conventional monoculture condition
(fold change of 1) and expressed as mean ± standard error of the mean. p value < 0.05 versus all conditions (*), all static conditions (#),
both conventional conditions (§), or conventional monoculture condition (@). ExL: Exoliver
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Results obtained from hepatocytes treated with acetaminophen
(Figure 5d) are diverse; acute overdose treatment induced low urea
production, vehicle albumin synthesis, increased aspartate aminotrans-
ferase (AST), and diminished alanine aminotransferase (ALT) and lactate
dehydrogenase (LDH) in conventional two‐dimensional cultures. Similarly
to conventional‐cultured hepatocytes, Exoliver‐cultured hepatocytes also
exhibited decreased urea, ALT and LDH production; nevertheless a
significant increase in albumin synthesis and a reduction in AST release to
the culture media were observed in response to acetaminophen
treatment.
Hepatocytes morphology after treatment with toxic drugs
confirmed lack of viability in conventional two‐dimensional cultures
(Figure 5e). Further mechanistic analysis of hepatocytes cell death in
response to toxicants revealed high levels of necrosis, as suggested
by elevated soluble keratin 18 (Figure 5f) in the culture media, with
no differences in apoptosis‐related caspase‐cleaved keratin 18
(Figure 5g).
To further study the applicability of Exoliver assessing hepato-
toxicity, the effects of 7‐day treatment with tolcapone were analyzed.
As shown in Supporting Information Figure 4, and very similar to what
was observed at Day 3, hepatocytes cultured by conventional methods
exhibited a profound deregulation in viability and function as
demonstrated by a marked decrease in urea and albumin synthesis,
together with the increased release of transaminases and LDH.
Interestingly, hepatocytes cultured in the device show higher
resistance to this toxicant in comparison with conventional.
4 | DISCUSSION
The current study demonstrates for the first time that it is possible to
maintain primary human hepatocytes in vitro when cocultured with
functional primary LSEC in a sinusoidal‐like milieu. The study has
been developed using a liver‐resembling device that mimics the
F IGURE 4 Assessment of cirrhotic primary human hepatocytes after 3 days of culture in conventional monoculture or dynamic coculture using
Exoliver. Synthetic capacity of hepatocytes was measured as albumin and urea secretion and cell phenotype markers as gene expression of the
transcription factor hnf4α, slc22a1, and abcc3. Data derive from n = 4 independent experiments were normalized to conventional monoculture
condition (fold change of 1) and expressed as mean ± standard error of the mean. *p value < 0.05 versus conventional culture. ExL: Exoliver
F IGURE 3 Primary healthy human and rat hepatocytes morphology after culture for 3 or 7 days in conventional monoculture or Exoliver
optimal configuration. Images were taken at 10× magnification [Color figure can be viewed at wileyonlinelibrary.com]
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F IGURE 5 Exoliver‐cultured hepatocytes response to acute drug‐induced injury. Hepatocytes viability was assessed as urea and albumin
synthesis and transaminases and LDH release to the culture media. Healthy human hepatocytes were cultured in the optimal Exoliver
configuration (with LSEC) or in conventional monoculture. After 24 hr of culture, hepatocytes received acute toxic insult and were cultured for
additional 24 hr with 100 μM troglitazone (a), 100 μM tolcapone (b), 1 mM diclofenac (c), or 40mM acetaminophen (d). Cell morphology (e) and
release of cell death markers (soluble keratin 18 and caspase‐cleaved keratin 18) (f,g) were analyzed. Images were taken at 10x magnification.
Data derived from n = 4 independent experiments were normalized to vehicle concentration (fold change of 1) and expressed as
mean ± standard error of the mean. *p value < 0.05 versus its corresponding vehicle. ALT: alanine aminotransferase; AST: aspartate
aminotransferase; ExL: Exoliver; K18: keratin 18; LDH: lactate dehydrogenase; LSEC: liver sinusoidal endothelial cells [Color figure can be
viewed at wileyonlinelibrary.com]
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unique architecture of the liver sinusoid allowing layered coculture of
multiple cell types with controlled endothelial shear stress stimula-
tion and paracrine communications, as it occurs in the human liver.
We herein demonstrate that the benefits of this coculture system
rely on the presence of functional LSEC. Indeed, the device benefits
are mainly lost in both suboptimal Exoliver configurations: a perfused
monoculture of hepatocytes or coculture of cells without biomecha-
nical stimulation. In the first scenario, and although indirect flow
stimulation per se might exert some beneficial effects on hepatocytes
(Dash et al., 2013; Kang et al., 2015; Rashidi, Alhaque, Szkolnicka,
Flint, & Hay, 2016), we observed that this configuration was inferior
to the coculture of hepatocytes with flow‐stimulated LSEC. In the
second situation, hepatocytes phenotype was lost in the absence of
endothelial shear stress probably due to LSEC dedifferentiation upon
isolation and in vitro culture (March, Hui, Underhill, Khetani, &
Bhatia, 2009).
However, our investigations demonstrate that LSEC functional
phenotype can be efficiently maintained under dynamic culture
(Marrone et al., 2013; Shah et al., 1997), ultimately leading to
hepatocytes maintenance (Dash et al., 2013). Underlying mechanisms
of such protection may derive from the fact that LSEC cultured in static
configurations become rapidly dysfunctional, driving molecular signal-
ing to hepatocytes that ultimately promote, or at least do not prevent,
their dedifferentiation. In addition, functional LSEC might release
soluble factors or membrane‐embedded entities that contribute to
maintain hepatocyte phenotype (Ding et al., 2010; Hu et al., 2014; Koch
et al., 2017). In fact, upregulation of hepcidin/hamp in Exoliver
cocultured hepatocytes (Supporting Information Figure 1D) supports
angiocrine communication from functional LSEC. We cannot discard
that future designs of the device, in which direct contact interactions
between cells may be allowed as it occurs in the sinusoids, would give
superior beneficial results than those herein described.
Interestingly, and most likely due to the singular design of the
device, a relative gradient in oxygen along the culture area was
observed (Supporting Information Figure 5A). Specialization of liver
cells along the portal triad—central vein axis is known as zonation,
and major drivers for such compartmentalization include nutrients,
hormones, and growth factors, but specially oxygen. Because
zonation directly affects macronutrient metabolism, morphology,
and xenobiotic transformation in hepatocytes, oxygen gradient could
indeed contribute to better reproduce the sinusoidal milieu and
therefore to the maintenance of hepatocytes in the device
(Kietzmann, 2017). Importantly, Exoliver‐cultured hepatocytes at
the inflow area were enriched in genes predominantly expressed in
periportal areas of the human liver, whereas hepatocytes at
the outflow predominantly expressed pericentral typical genes
(McEnerney et al., 2017; Figure 5b,c).
Considering the beneficial effects of this biosystem in preserving the
phenotype of healthy human hepatocytes, we subsequently aimed at
demonstrating its translational potential in two clinically relevant areas.
Data demonstrating maintenance of the phenotype of human cirrhotic
hepatocytes creates a new preclinical stage to test the efficacy of novel
therapeutic options for the chronic liver disease. Indeed, the device may
offer highly valuable information about the effects of a certain chemical
entity in a human liver‐like environment just before administering it to
humans. As an example, data from our team using the herein described
device demonstrate that a caspase inhibitor that is currently at clinical
evaluation for the treatment of chronic liver disease improves human
cirrhotic hepatocytes without evidence of toxicity (Gracia‐Sancho,
Contreras, Vila, Garcia‐Caldero, Spada, & Bosch, 2016).
Further translational studies focused on the field of drug‐induced
liver injury. Interestingly, Exoliver‐cultured hepatocytes responded
significantly different to hepatotoxic drugs than dedifferentiated
cells. These data suggest that concentrations of drugs previously
proposed to be hepatotoxic in vitro may not truly promote cell death
when tested in functional hepatocytes. Vice versa, it is now
conceivable that some drugs that were withdrawn due to toxicity
in two‐dimensional primary cultures could have not been harmful if
tested in a more physiological environment. Although primary
hepatocytes are considered the current gold standard for short‐term
in vitro toxicant testing, they are severely hindered by the lack of
three‐dimensional organization, nonparenchymal cells, nutrient ac-
cess, and cell–cell interactions, which can be found in liver‐on‐a‐chip
devices. For this reason, preclinical research should consider the
analysis of toxicity in physiologically resembling devices, which may
provide valuable data that would complement results obtained in
two‐dimensional hepatocytes cultures.
We are aware that our study has limitations; probably the most
important is that our device does not entirely recapitulate the diversity
of cells found in the liver sinusoid. Adding extra cell layers, with hepatic
stellate cells and/or macrophages, would probably increase its
biological resemblance. Nevertheless, our data show that adding
perfused LSEC per se is able to maintain hepatocytes phenotype,
suggesting that LSEC play a major role in hepatocyte homeostasis.
It is true that future perspectives on liver bioengineering
research are set in generating improved in vitro culture systems
for modeling human diseases and performing valuable assays. The
development of in vitro devices that address systemic human biology
using liver‐resembling devices in combination with other organ
biosystems is highly needed (Coppeta et al., 2017; Maschmeyer et al.,
2015). The herein described platform may contribute to create these
body‐on‐a‐chip structures that will ultimately allow a global under-
standing of prodrugs and metabolites’ effects in various organs.
To sum up, our study describes a novel bioengineered device that
resembles the human liver in vitro, currently representing the
preclinical setup closest to the bedside. Altogether encourages its
applicability for the study of liver diseases and toxicology.
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